Electromed, Inc.
AMEX•ELMD
CEO: Mr. James L. Cunniff
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2010-08-13
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Contact Information
Market Cap
$232.12M
P/E (TTM)
28.3
4.1
Dividend Yield
--
52W High
$35.56
52W Low
$17.73
52W Range
Rank24Top 10.8%
5.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q1 2026 Data
Revenue
$16.89M+15.13%
4-Quarter Trend
EPS
$0.26+52.94%
4-Quarter Trend
FCF
-$98.00K-104.31%
4-Quarter Trend
2026 Q1 Earnings Highlights
Key Highlights
Revenue Growth Strong Net revenues totaled $16.89M USD for the quarter, increasing 15.1% compared to prior period.
Net Income Surges 44.9% Net income reached $2.14M USD, driven by increased revenue and gross profit performance.
Hospital Sales Accelerate Hospital revenue grew substantially by 51.7% to $1.05M USD due to increased sales focus.
Basic EPS Improvement Basic earnings per share increased to $0.26 USD from $0.17 USD in the prior year period.
Risk Factors
Operating Cash Flow Decline Net cash provided by operating activities fell significantly to $169K USD from $2.31M USD.
Working Capital Shifts Large $2.35M decrease in accrued compensation negatively impacted cash provided by operations.
Inventory Investment Inventories increased by $515K USD during the quarter, consuming operational cash resources.
Credit Facility Maturity Revolving line of credit for $2.5M USD is set to expire in December 2025, requiring renewal.
Outlook
Liquidity Forecast Positive Working capital of $35.8M USD and available credit expected to meet liquidity needs for twelve months.
Share Repurchase Activity Company utilized $1.00M USD to repurchase common stock under the recently approved authorization.
SG&A Expense Increase SG&A expenses rose 9.6% due to higher sales headcount and ongoing compensation benchmarking efforts.
Tax Legislation Evaluation Evaluating impact of OBBBA legislation regarding deductibility of U.S.-based research expenditures.
Peer Comparison
Revenue (TTM)
ARAY$450.90M
INGN$347.03M
HCAT$316.06M
Gross Margin (Latest Quarter)
MXCT92.4%
86.8%
86.4%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| SGHT | $342.08M | -7.3 | -61.6% | 35.0% |
| PROF | $248.26M | -6.3 | -86.8% | 0.7% |
| ELMD | $232.12M | 28.3 | 18.7% | 0.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.3%
Moderate Growth
4Q Net Income CAGR
2.8%
Profitability Slowly Improving
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Feb 10, 2026
EPS:$0.27
|Revenue:$18.05M
Reports
All Years
Form 10-Q - Q1 2026
Period End: Sep 30, 2025|Filed: Nov 12, 2025|Revenue: $16.89M+15.1%|EPS: $0.26+52.9%BeatForm 10-K - FY 2025
Period End: Jun 30, 2025|Filed: Aug 26, 2025|Revenue: $64.00M+17.0%|EPS: $0.90+50.0%BeatForm 10-Q - Q3 2025
Period End: Mar 31, 2025|Filed: May 13, 2025|Revenue: $15.68M+13.1%|EPS: $0.22+29.4%BeatForm 10-Q - Q2 2025
Period End: Dec 31, 2024|Filed: Feb 11, 2025|Revenue: $16.26M+18.7%|EPS: $0.23+15.0%BeatForm 10-Q - Q1 2025
Period End: Sep 30, 2024|Filed: Nov 12, 2024|Revenue: $14.67M+19.0%|EPS: $0.17+834.1%BeatForm 10-K - FY 2024
Period End: Jun 30, 2024|Filed: Aug 27, 2024|Revenue: $54.72M+13.8%|EPS: $0.60+62.2%BeatForm 10-Q - Q3 2024
Period End: Mar 31, 2024|Filed: May 7, 2024|Revenue: $13.87M+14.9%|EPS: $0.17+30.8%BeatForm 10-Q - Q2 2024
Period End: Dec 31, 2023|Filed: Feb 13, 2024|Revenue: $13.69M+16.7%|EPS: $0.20+66.7%Beat